What are the leading stocks in health China?
The health industry refers to a composite industry based on biotechnology, information technology and modern medicine, covering many fields such as biomedical engineering, traditional Chinese medicine, medical and health services. The following editorial brings what are the leading stocks in health China, which is of great benefit to all of you, take a look together.
What are the leading stocks in health China
1, and the good shares (12.34 +0.33%, diagnosis)
In the field of health care services to test the PPP model for many years, the recent announcement of the third people's hospital in Henan Yushi County, Guizhou Pingtang County, the Bureau of Health Bureau, to carry out the construction of medical services.
Hejia shares and Guizhou Pingtang County cooperation projects with a total investment of up to 2.9 billion yuan for the company's future development. Hejia is a pioneer in the transformation of medical device companies into the medical service industry, especially in the fine molecule areas of hemodialysis, rehabilitation and medical informatization highlights.
2, Yibai Pharmaceuticals (15.40 +0.13%, diagnosis)
As a leading anti-tumor drug enterprise, in recent years, actively to the oncology medical service industry transformation. 2016 April, the company's subordinate Anhui Province oncology doctor group was formally established,
has acquired a tertiary level B hospitals, signing up for 11 non-equity relationship with the oncology treatment center, 8 In the future, it will develop according to the model of a large physician enterprise group. Medical service is expected to become an important performance growth point of the company in the future.
3, Yueyue medical (22.93 +2.92%, diagnosis)
It is the largest rehabilitation care, medical oxygen and medical clinical series of medical equipment specialized production enterprises, our country's leading enterprises in the medical equipment industry. It produces more than 50 varieties of products, which is one of the most abundant product varieties among domestic manufacturers in the same industry.
According to the company's official website, at present, the company's oxygen concentrator, nebulizer, blood pressure monitor, stethoscope, ultra-slight oxygen valve five products of the market share of the domestic first, of which the oxygen concentrator product is to reach the level of global sales of the first.
Wheelchair carts and electronic blood pressure monitors have the second largest market share in China. In addition, the company also actively enter the Internet medical, to create a cloud health platform for chronic disease management. The company's perfect product and industrial layout, is expected to fully benefit from the outbreak of the elderly medical market.
General health stocks what leading stocks
A, Yuexin Health (002162), Shanghai Yuexin Health Group Co., Ltd. is engaged in the business of large-scale health industry, architectural ceramics business and ecological health building materials business. The company's total operating income of 1.195 billion in 2020, an increase of 2.44%; gross profit of 3. Net profit of 38.1 billion yuan, net profit of 35.17 million yuan.
Two, Baiyunshan (6000332) (1) Chinese and Western patent medicines, chemical raw materials, natural medicines, biomedicine, chemical raw materials intermediates research and development, manufacturing and sales; (2) Western medicine, traditional Chinese medicine, and medical equipment wholesale, retail, and import and export business; (3) research and development, production and sales of health products; and (4) medical services, health management, health care and pension and other health Industry investment, etc. In 2020, the company's total operating income of 61.67 billion yuan, an increase of -5.05%; gross profit of 10.44 billion yuan, net profit of 2.628 billion yuan;
Three, Huabang Health (002004), February 20, Huabang Health replied to an investor's question, said that, at present, the company has determined the development strategy of the big health, focusing on the pharmaceutical and health care Main business. The company will introduce strategic investors according to the overall development of strategic planning and various factors.In 2020, the company's total operating income was 10.88 billion, an increase of 7.78%; gross profit of 44%. Net profit of 5.5 billion yuan.6 billion yuan.
Four, Guoxin Health (000503), the two sides will *** together to promote the innovative development of intelligent medical and large-scale health industry in Hefei, focusing on the construction of health and safety service system. The company's total operating income in 2020 2. year-on-year growth of 5.9 billion yuan.62%; gross profit of 30.45 million, net profit of -242 million yuan.
fifth, jiangsu wuzhong (600200), jiangsu wuzhong announcement said, in the macroeconomic environment and industrial development situation changes, the company established the pharmaceutical and health industry as the core industry development direction. On the one hand, adhere to the depth of the main business of the pharmaceutical manufacturing industry to cultivate, on the other hand, choose the opportunity to extend in other health sub-fields; in order to accurately reflect the company's business structure and the direction of strategic development, so that the company's name and scope of business with the company's strategic planning and business match, the company plans to change the name and scope of business, and to amend the corresponding articles in the articles of association of the company.
What are the leading stocks of health care products
The leading stocks of health care products concept are:
Thomson's 300146: leading health care products. BY-HEALTH P/E ratio of 26.15, 2020 revenue growth of 15.83% year-on-year to 6.095 billion, gross profit margin reached 62.82%.
Domestic nutritional health products leader, but also dietary supplements industry pharmacies and online dual channel leader; products include protein powder, vitamins, liquid calcium, etc., brands include "BY-HEALTH", Jianliduo, etc..
In the last 7 days, BY-HEALTH shares rose 3.95%, 2022 shares fell -4.25%, the highest price of $26.73, market capitalization of 45.228 billion yuan.
Dong A Gum 000423: the company's 14th Five-Year Plan for new product development: the direction of pharmaceuticals (Colla Corii Asini Classic Famous Formulas, Colla Corii Asini, Colla Corii Asini, Colla Corii Asini Runs the Lungs, etc.), the direction of health care and functional food (Colla Corii Asini Yushen, beauty and anti-aging, menstrual regulation and preparation for pregnancy, improve immunity, etc.). At present, there is no plan to launch new products such as Colla Corii Asini drinks.
Lizhu Group 000513: potential leading respiratory inhalation preparations, the main products include ginseng qi fu zheng injection, lizhu deluxe (potassium citrate) series of products, antiviral particles HIV antibody diagnostic reagents. The company's business in western pharmaceuticals, APIs, health care products and other stable growth.
Sihuan Bio 000518: research and development, production and sales of drugs and health products.
What are the leading stocks in the health industry
1, Dean Diagnostics (28.30 +1.25%, diagnostic shares): the layout of high-end precision diagnostic technology platform, cooperation *** build business growth is rapid, has been in a number of tertiary hospitals customers extend *** build precision platform.
2, the United States and Hong Kong Biological (23.45 +0.04%, diagnostic shares): has obtained 145 in vitro diagnostic reagents product registration certificates, covering biochemical, blood cells and other fields.
3, jiuzhou tong (20.04 +0.50%, diagnosis): its wholly owned subsidiary good pharmacist pharmacy and kangsheng medicine signed a strategic cooperation framework agreement, plans to gradually realize the kangsheng edge of the series of medicines, health food series for cooperation within 3 years.
4, Lucking health (6.26-1.11%, diagnosis): the company is one of the earlier engaged in the development and production of home sauna equipment, is to promote the health of the sauna into the domestic ordinary family of the forerunner. The main products mainly include home far-infrared sauna room and portable sauna products two categories.
5, Beida medicine (000788): the acquisition of Beida medicine to complete the business expansion. The company in 2011 to the Beida international hospital group directional hair acquisition to buy 100% of the equity of Beida medicine. North medicine medicine and its subsidiaries from 2011 into the company statement. The company added into the drug, medical equipment sales and distribution business, the pharmaceutical industry chain is further extended.
Top 10 Leading Chinese Medicine Stocks
The top 10 leading Chinese medicine stocks are Pientzehuang, Yunnan Baiyao, Jiuzhitang, Essence Pharmaceuticals, Tongrentang, Baiyunshan, Kangyuan Pharmaceuticals, Jiangzhong Pharmaceuticals, Guangyuduan, and Ma Yinglong.
The market size of China's healthcare service industry reached 4.6 trillion yuan in 2019, with a 2015-2019 CAGR of 12%, and is expected to reach 10 trillion yuan in 2030.
Of these, China's traditional Chinese medicine (TCM) health industry has also expanded along with the development of the medical and health service industry.In 2019, the TCM health market size was RMB 917 billion, and the in-depth analysis of the TCM industry and the research and analysis report on the guidance of the 13th Five-Year Plan for the development of the industry predicts that the size of the TCM industry in 2030 is expected to reach RMB 224.2 billion, with an estimated 2019-2030 CAGR of 11.3%.